China approves Hengrui Medicine trial: 19 analysts target Hengrui Medicine stock at CNY 70.79

Published on 10/25/2026 at 02:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

China approved Hengrui Pharma's prostate cancer phase 3 trial on October 23, 2026. Hengrui Medicine stock closed CNY 47.02 versus CNY 46.00.

Research pipeline and reporting dates

China approved a phase 3 prostate cancer trial on October 23, 2026.
Hengrui Pharma will present 64 research findings at ESMO 2026.
Hengrui Medicine stock closed at CNY 47.02 on October 23, 2026.

Bank of Shanghai, CNE0000014W7, Illustration mit AI erstellt.

Hengrui Medicine (CNE0000014W7) won Chinese approval for a phase 3 prostate cancer trial on October 23, 2026, while 19 analysts tracked the Shanghai-listed stock with an average target of CNY 70.79. The trial approval is the latest development in a pipeline that will also produce new clinical data at the ESMO Congress.

Prostate trial adds a new milestone

Zonebourse reported the phase 3 approval on October 23, 2026. The report identifies the issuer as Jiangsu Hengrui Medicine, ticker 600276, and places the shares on the Shanghai Stock Exchange.

The development gives the company another late-stage oncology project, but the clinical trial remains an evidence-building step rather than a commercial launch. That distinction matters because the next valuation test is likely to come from clinical updates and the scheduled third-quarter report.

What does the research pipeline add?

On October 21, 2026, PR Newswire said Hengrui Pharma would present 64 research findings at ESMO 2026. Three studies were selected for Proffered Paper presentations, three for Rapid Oral sessions, 32 for Posters and 26 for E-Posters.

The ESMO program includes phase 3 work on trastuzumab rezetecan in breast cancer and ruzaltatug rezetecan in lung cancer. MarketScreener lists the next quarterly results for October 27, 2026.

Three dated steps in the pipeline

On September 29, 2026, Hengrui entered a licensing agreement for HRS-1596 with Novo Nordisk worth up to USD 2.6 billion, according to MarketScreener. On October 21, 2026, the company announced 64 ESMO research findings through PR Newswire. On October 23, 2026, China approved the phase 3 prostate cancer trial, as reported by Zonebourse.

Two dates set the next test

The next scheduled milestone is the ESMO presentation of interim phase 3 HERON-Lung01 data on October 26, 2026, followed by Hengrui's third-quarter results on October 27, 2026.

Shanghai valuation stays event-driven

Hengrui Medicine closed at CNY 47.02 on the Shanghai Stock Exchange on October 23, 2026, compared with a previous close of CNY 46.00. The same market context puts the 52-week range at CNY 41.89 to CNY 67.85 and market capitalization at CNY 299.9 billion.

Hengrui Medicine's next two dated catalysts are the October 26, 2026, ESMO presentation and the October 27, 2026, third-quarter results.